Amine Addition Salt Of The Acid Patents (Class 514/554)
-
Publication number: 20100323895Abstract: The present invention relates to a cleaning preparation, namely to a cleaning, disinfecting, sanitizing and sterilizing preparation. Said preparation comprises a mixture of cationic microbiocides and non-ionic surfactants.Type: ApplicationFiled: March 12, 2009Publication date: December 23, 2010Inventor: Goerge V. Garner
-
Patent number: 7829133Abstract: A surgical suture material with an antimicrobial surface is described, the surface exhibiting a coating containing a) at least one fatty acid, b) octenidine dichloride and/or dequalinium chloride and c) optionally oligomeric lactic acid esters. In addition, a process for coating surgical suture material is described which is characterized by the fact that the thread material is wetted with a homogeneous methanolic solution of octenidine dichloride and/or dequalinium chloride and subsequently the methanol is evaporated, a coating forming on the thread surface.Type: GrantFiled: October 24, 2007Date of Patent: November 9, 2010Assignee: Heraeus Kulzer GmbHInventors: Sebastian Vogt, Klaus-Dieter Kuhn, Hubert Buchner
-
Publication number: 20100273879Abstract: The invention relates to a method for producing acylglycinates of formula (I) wherein R1 represents a linear or branched, saturated alkanoyl group having between 6 and 30 carbon atoms, or a linear or branched, mono- or polyunsaturated alkenoyl group having between 6 and 30 carbon atoms, and Q+ represents a cation selected from the alkali metals Li+, Na+ and K+, characterised in that glycine comprises fatty acid chloride R1Cl, wherein R1 which has the meaning given in formula (I), is provided in water and in presence of a basic alkali compound, the cations Q+ are selected from Li+, Na+ and K+, but in the absence of organic solvents, is reacted at between 30-35 DEG C, and the proportion of fatty acid chloride R1Cl containing acyl groups R1 having 18 or more carbon atoms, in relation to the total amount of used fatty acid chloride, is less than 2.0% in wt.Type: ApplicationFiled: November 14, 2008Publication date: October 28, 2010Applicant: Clariant Finance (BVI) LimitedInventors: Peter Klug, Franz-Xaver Scherl
-
Patent number: 7820715Abstract: Crystals comprising (2R)-2-propyloctoic acid and an amine which retain the pharmacological effect of (2R)-2-propyloctoic acid and can be safely used as a medicinal raw drug for peroral solid preparations. Of these crystals, the crystals especially with dibenzylamine are advantageous because not only the crystals themselves are useful as a medicinal raw drug but also use of the crystals as an intermediate can yield (2R)-2-propyloctoic acid having an optical purity exceeding 99.5% e.e., which has not been obtained hitherto.Type: GrantFiled: April 27, 2005Date of Patent: October 26, 2010Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Tomoyuki Hasegawa, Yasufumi Kawanaka, Eiji Kasamatsu
-
Patent number: 7820716Abstract: The present invention is directed to two new polymorph Form V and Form F of desvenlafaxine succinate, to processes of their preparations, pharmaceutical composition comprising such materials and their use in therapy. Form V is prepared from recrystallizing desvenlafaxine succinate in a mixture of tetrahydrofuran and ethanol. Form F is obtained from recrystallization of desvenlafaxine succinate in a mixture of cyclohexane and polar solvents such as ethanol, THF, methanol or isopropyl alcohol.Type: GrantFiled: November 5, 2007Date of Patent: October 26, 2010Assignee: Mai De LtdInventors: Cai Gu Huang, Hui Min He Huang
-
Patent number: 7815942Abstract: Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.Type: GrantFiled: February 22, 2006Date of Patent: October 19, 2010Assignee: Teva Pharmaceutical Industries, Ltd.Inventor: Tirtza Berger Peskin
-
Patent number: 7786167Abstract: The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration.Type: GrantFiled: October 10, 2007Date of Patent: August 31, 2010Assignee: IDEXX Laboratories, Inc.Inventors: Yerramilli V. S. N. Murthy, Robert H. Suva
-
Publication number: 20100204324Abstract: An optically active N-(?-mercaptopropionyl)glycine, i.e., R-(?)-N-(?-mercaptopropionyl)glycine or S-(?)-N-(?-mercaptopropionyl)glycine, a preparation method thereof, a pharmaceutical preparation containing the compound or a pharmaceutically acceptable salt or ester thereof, and use of the same in preparation of detoxification medicament for improving metabolism, are provided.Type: ApplicationFiled: December 28, 2007Publication date: August 12, 2010Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.Inventors: Yong Wang, Cang Zhang, Zaijin Teng, Wenping Zhang, Jinye Qian
-
Patent number: 7767712Abstract: The present invention relates to a storage-stable aqueous or gel-like composition or solution comprising a magnesium compound selected from a magnesium salt or a magnesium complex compound, and L-carnitine, and the use thereof for the preparation of a medicament for supporting metabolism, in particular in muscle tissue, and for supporting muscle structure, and its use as food supplement or in the veterinary sector as animal feed additive, in particular for horses, poultry, pigeons, pigs, cattle, sheep and camels.Type: GrantFiled: May 3, 2007Date of Patent: August 3, 2010Assignee: Verla-Pharm Arzneimittelfabrik Apotheker H.J.v. Ehrlich GmbH & Co. KGInventor: Günter Hopf
-
Patent number: 7754765Abstract: In various aspects, the invention provides methods for treating ocular inflammation using copper chelating compounds, such as compounds other than D-penicillamine. In some embodiments, such compounds may be polyamines, such as triethylenetetramine or tetraethylenepentamine. For example, the present invention provides methods for treating inflammation secondary to ocular laser therapy.Type: GrantFiled: May 30, 2003Date of Patent: July 13, 2010Assignee: Radical Vision Therapeutics IncInventors: Xuefeng Wang, Jing Z. Cui, Joanne A. Matsubara
-
Publication number: 20100173994Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.Type: ApplicationFiled: July 21, 2009Publication date: July 8, 2010Inventors: Marco Jonas, Irene Vaulont, Antonio Soi, Gunther Schmidt
-
Patent number: 7749541Abstract: Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.Type: GrantFiled: February 22, 2006Date of Patent: July 6, 2010Assignee: Teva Pharmaceutical Industries, Ltd.Inventor: Tirtza Berger Peskin
-
Publication number: 20100150851Abstract: Novel compositions comprising anionic-cationic complexes as conditioning agents for use in products that improve the appearance and feel of skin and hair are well known. This invention describes the use of additional cationic surfactant in combination with an anionic-cationic complex made from a fatty alkyl dialkylamine and a “dicarboxylic acid”, preferably a dimer acid. This combination provides exceptional conditioning for hair, improving both wet and dry combing. It also makes very stable oil-in-water emulsions, and adds a slippery feel and lubricity to shaving and skin cleaning products.Type: ApplicationFiled: April 11, 2008Publication date: June 17, 2010Applicant: ALZO INTERNATIONAL, INC.Inventors: Albert A. Zofchak, John Carson, Paul Slavashevich
-
Publication number: 20100144773Abstract: The present invention relates to pharmaceutical compositions for the intranasal administration comprising a therapeutically effective amount of a compound of formula (I) or pharmaceutically acceptable salts thereof. Preferably, the pharmaceutically acceptable salt is selected from the group consisting of choline salt, sodium salt, potassium salt, and thiamine salt. Further, the present invention relates to methods for intranasal delivering compound of formula (I) and pharmaceutically acceptable salts thereof. Further, the present invention relates to methods for treating a neurodegenerative disease with using compositions of the present invention.Type: ApplicationFiled: August 2, 2007Publication date: June 10, 2010Inventor: Igor Anatolievich Pomytkin
-
Publication number: 20100047360Abstract: The present invention provides unbranched aliphatic polyamines for use in therapy, particularly for use in the treatment of psoriasis and compositions containing polyamines.Type: ApplicationFiled: March 14, 2007Publication date: February 25, 2010Applicant: Bioforskining Pharma ASInventors: Jo Klaveness, Geir Havard Kvalheim
-
Patent number: 7645742Abstract: A composition for enhancing cellular energy that includes creatine, L-arginine-?-ketoglutarate, D-ribose, L-carnitine, L-citrulline, and pyruvate. The composition is administering to a subject to enhance cellular energy, to increase relative intensity of physical activity performed by the subject, to increase endurance of the subject during the physical activity and to increase the muscle mass of the subject.Type: GrantFiled: June 22, 2005Date of Patent: January 12, 2010Assignee: Advocare International, L.P.Inventor: Sidney Stohs
-
Patent number: 7611730Abstract: The invention relates to a medicament containing the racemate of tramadol in a retarded form and the (+)-enantiomer of tramadol in a non-retarded form.Type: GrantFiled: August 15, 2003Date of Patent: November 3, 2009Assignee: Grunenthal GmbHInventors: Johannes Bartholomäus, Elmar Josef Friderichs
-
Publication number: 20090270500Abstract: This invention relates to novel 4-trimethylammoniobutyrates of the formula wherein A1, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments.Type: ApplicationFiled: April 28, 2009Publication date: October 29, 2009Inventors: Mirjana Andjelkovic, Simona M. Ceccarelli, Odile Chomienne, Patrizio Mattei
-
Patent number: 7585850Abstract: The invention is directed to compositions and methods which permit the oral use of adenosine and adenosine phosphates for cardiovascular applications such as pulmonary artery hypertension, cardiac failure and other diseases. Certain compositions in accordance with the invention have enhanced AMP gastrointestinal bioavailability and thus efficacy. The invention prolongs the activity of adenosine and adenosine phosphates when administered intravenously. In particular, the invention contemplates methods of treating several human (as well as animal) cardiovascular and neurological medical conditions that could be improved by an effective amount of adenosine, ATP or AMP combined with dialkylaminoalcohols and their salts.Type: GrantFiled: February 9, 2005Date of Patent: September 8, 2009Assignee: Adenobio N.V.Inventor: Philipe Gorny
-
Patent number: 7550624Abstract: Pharmaceutically active salts and esters of 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol and 3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol, and methods of using the same for treating or inhibiting increased urinary urgency or urinary incontinence and/or pain.Type: GrantFiled: December 6, 2004Date of Patent: June 23, 2009Assignee: Gruenenthal GmbHInventors: Joerg Holenz, Helmut Buschmann
-
Patent number: 7534816Abstract: An aqueous composition for oral care application comprising solution of an amidobetaine of the following general Formula I is disclosed; in which R is an alkyl of coconut fatty acids, preferably hydrogenated coconut fatty acids, or a fatty acid mixture group which, on the average, corresponds to coconut fatty acids, wherein the solution has a solids content of 36% by weight, a pH of 4.5 to 6, an alkylamidopropyldimethyl amine content of not more than 0.1% by weight, and a free fatty acid content less than 0.5% by weight, sodium chloride content of 6.0% max and dimethylaminopropylamino betaine (from N,N-dimethyl amino propyl 1,3-diamine (DMAPA) and monochloroacetic acid) content of 30 ppm max, free sodium monochloroacetic acid content of 5 ppm max and free N,N-dimethylamino propyl 1,3-diamine content of 5.0 ppm max.Type: GrantFiled: January 6, 2006Date of Patent: May 19, 2009Assignee: Galaxy Surfactants LimitedInventors: Nirmal Koshti, Bharat Parab, Shubhangi Naik
-
Patent number: 7504118Abstract: Materials derived from cinnamon can be administered orally to humans or animals for the purpose of controlling blood glucose as well improving glucose tolerance. Controlling glucose metabolism is essential for those with impaired glucose metabolism as is the case for those with Type II diabetes where insulin function is not properly functioning. Such administration can also be used for the purpose of enhancing nutrient transport for purposes of athletic performance and controlling bodyweight and body fat levels. Similarly related, such administration can also be used for the purpose of enhancing creatine transport into excitable tissues such as skeletal muscle. The material can be administered as extracts of cinnamon and can be administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.Type: GrantFiled: April 12, 2004Date of Patent: March 17, 2009Assignee: FHG CorporationInventors: Peter Miller, Timothy Romero
-
Publication number: 20090042983Abstract: The use of L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicine useful for reducing the number of deaths caused by acute myocardial infarction and for improving the short-and-long-term prognosis in the patients treated with it, in which L-carnitine is administered parenterally within the first few hours of onset of the symptoms of acute myocardial infarction at an initial dose of 9 grams a day for 5 days, after which the treatment is continued at a dose of 4 grams a day by the enteral routeType: ApplicationFiled: September 15, 2008Publication date: February 12, 2009Applicant: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Aleardo Koverech
-
Patent number: 7465812Abstract: The present invention relates to a method of production and the use of a compositional ingredient. Specifically, the present invention relates to hydrosoluble stable organic salts of creatine and pyroglutamic acid. The compositional ingredient may be useful for the regulation of athletic and cognitive functions.Type: GrantFiled: July 17, 2007Date of Patent: December 16, 2008Assignee: New Cell Formulations Ltd.Inventor: Michele Molino
-
Patent number: 7449315Abstract: Energy-reversible acyl conjugates, intermediates, and related compositions are disclosed.Type: GrantFiled: March 30, 2007Date of Patent: November 11, 2008Assignee: Cryolife, Inc.Inventors: Carl W. Gilbert, Eleanor B. McGowan, Kirby S. Black, T. Gregory P. Harper
-
Patent number: 7439268Abstract: The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration.Type: GrantFiled: July 18, 2003Date of Patent: October 21, 2008Assignee: Idexx LaboratoriesInventors: Yerramilli V. S. N. Murthy, Robert H. Suva
-
Publication number: 20080241080Abstract: The present invention provides a composition comprising olive oil, trimethylglycine and xylitol for treating xerostomia and disorders associated thereto, with very good results in increasing the unstimulated salivary flow, in alleviating the symptoms of xerostomia, including the pain associated to xerostomia, as well as improving the quality of life of affected persons. The composition of the invention has also been proved to protect dentin against demineralization in acid conditions.Type: ApplicationFiled: February 22, 2008Publication date: October 2, 2008Applicant: BIOCOSMETICS, S.L.Inventor: DEBORA RODRIGUEZ-VILABOA
-
Patent number: 7410655Abstract: An anticancer agent containing platinum preparation, humic substances, water and sodium chloride. Potassium tetrachloroplatinate is used as a platinum compound and lignohumic acid ammonium salts are used as humic substances taken in the following ratio of components per 1 ml of solution: lignohumic acid ammonium salts 0.18-0.22 mg potassium tetrachloroplatinate 0.020-0.040 mg sodium chloride isotonic solution 0.97-0.99 ml distilled water up to 1.Type: GrantFiled: February 20, 2002Date of Patent: August 12, 2008Assignee: Nobel Limited Liability CompanyInventors: Valery Pavlovich Shipov, Nadezhda Vasilievna Trofimova, legal representative, Evgeny Sergeevich Pigarev, Aleksandr Ivanovich Popov, Viktor Nikolaevich Ivanov, Valery Afanasievich Trofimov
-
Publication number: 20080161387Abstract: The present invention provides new salts and/or addition compounds and/or complex compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, ?-ketoglutaric acid, oxalic acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, sulfuric acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These salts have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the salts come to the fore.Type: ApplicationFiled: March 2, 2006Publication date: July 3, 2008Inventors: Thomas Gastner, Hans-Peter Krimmer
-
Publication number: 20080139636Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).Type: ApplicationFiled: June 20, 2007Publication date: June 12, 2008Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
-
Publication number: 20080114064Abstract: The invention relates to a compound selected from one or more of the following: a tris (hydroxymethyl) methylamine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl (2-phenylethyl) amino]-2-oxoethoxy}phenyl) propanoic acid; an ethanol amine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl (2-phenylethyl) amino]-2-oxoethoxy}phenyl) propanoic acid; or a pharmaeutical composition comprising the compound.Type: ApplicationFiled: December 14, 2005Publication date: May 15, 2008Applicant: ASTRAZENECA ABInventors: Rebecca J. Booth, Mikael Dahlstrom
-
Publication number: 20080103111Abstract: A multi-component compound for the simultaneous treatment of nicotine addiction and the side effects of nicotine withdrawal, such as excessive appetite. The first component is a bivalent negative sulfur compound in an amount effective to control nicotine craving or the withdrawal symptoms resulting from nicotine withdrawal. The bivalent negative sulfur is selected from a group that includes, but is not limited to, alkyl sulfides, colloidal sulfur, hydropersulfides, organic thio compounds or their salts. The second component is a serotonin precursor, such as tryptophan or its derivative 5-HTP, which is used to assist the body in producing more serotonin which in turn suppresses appetite. The appetite suppressant(s) are combined with the bivalent negative sulfur compound(s) to provide a single compound that reduces nicotine craving and simultaneously suppresses increased appetite resulting from nicotine withdrawal.Type: ApplicationFiled: October 30, 2006Publication date: May 1, 2008Inventor: Harlan Clayton Bieley
-
Publication number: 20080081798Abstract: A pharmaceutical combination comprising at least a triptan and the trimebutine compound [hydrogenated maleate of 2-dimethyl-amino-2-phenylbutyl-3,4,5-trimetoxybenzoate] and an anti-inflammatory or simple analgesic for the treatment of attacks of migraine and other headaches is provided. More particularly, the present invention discloses a pharmaceutical combination comprising triptan and trimebutine for the treatment of migraine attacks. The present invention further discloses blisters and packs containing said pharmaceutical combinations.Type: ApplicationFiled: October 3, 2006Publication date: April 3, 2008Inventor: Abouch Valenty Krymchantowski
-
Publication number: 20080076721Abstract: The present invention relates to the use of naturally occurring methylated branched chain fatty acids, precursors, or derivatives such as but not limited to 3,7,11,15-tetramethyl-2-Hexadecen-1-ol (phytol), 3,7,11,15-tetramethylhexadec-2-enoic acid (phytenic acid), 3,7,11,15-tetramethylhexadecanoic (phytanic acid) or 2,6,10,14-tetramethylpentadecanoic (pristanic acid) as amino acid salts for cosmetic, dietary supplement, or pharmaceutical compositions, which are useful in increasing the variables associated with physical performance for the regulation of athletic function.Type: ApplicationFiled: September 25, 2006Publication date: March 27, 2008Inventors: Sal Abraham, Shengli Jiang
-
Publication number: 20080063689Abstract: A problem with optimizing the effects of creatine has been the need to utilize large amounts of high glycemic carbohydrates to spike insulin in order to augment the flow of creatine (and other nutrients) into the muscle cell. Based upon current research, an insulin response strong enough to ensure absorption is possible without the need for dramatic carbohydrate load. Utilizing anthocyanins, such as cyanidin-3-glycoside and other potentiators, creatine can be absorbed by the muscles without overloading the system with excess calories from glucose (carbohydrates). U.S. Patent Application Publication No. 20040224035, a considerably lower daily intake of carbohydrates is necessary to achieve creatine absorption.Type: ApplicationFiled: September 12, 2006Publication date: March 13, 2008Inventor: Mike Farber
-
Patent number: 7335384Abstract: The present disclosure describes a novel composition for the treatment and/or prevention of neurogenic inflammation. Such composition is also useful in the treatment and/or prevention of disease states and conditions associated with neurogenic inflammation. Such disease states and conditions include, but are not limited to, migraine headache, arthritis and fibromyalgia. The composition comprises nutrient compounds in a novel combination and formulation to treat and/or prevent neurogenic inflammation and disease states and conditions associated therewith. By reducing neurogenic inflammation, the compositions of the present disclosure reduce the symptoms associated with neurogenic inflammation, such as pain and systemic inflammation in general.Type: GrantFiled: March 17, 2006Date of Patent: February 26, 2008Assignee: 4K Nutripharma InternationalInventor: F. Mahnaz Khaled
-
Publication number: 20080044462Abstract: Pharmaceutical compositions for transdermal administration containing a fatty acid salt, a dicarboxylic acid salt, an alkyl sulfonic acid salt, an aryl sulfonic acid salt, or an alkyl aryl sulfonic acid salt of an unstable active agent, such as bupropion free base or a derivative of burpropion free base, such as bupropion free base or derivative of bupropion free base, paroxetine, fluvoxamine, fluoxetine, sertraline, venlafaxine, duloxetine, and metabolites and derivatives thereof are described herein. The composition may also contain one or more antioxidants. The compositions can be prepared by forming the bupropion salt followed by addition of the antioxidant. Alternatively, bupropion can be combined first with the antioxidant followed by addition of the acid to form the salt. The compositions can be administered as a gel, cream, lotion, ointment, or patch and typically contain a pharmaceutically acceptable carrier and optionally one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: April 6, 2007Publication date: February 21, 2008Inventors: Mark W. Trumbore, Roman V. Rariy, Jane C. Hirsh, Mark Hirsh
-
Publication number: 20080031828Abstract: The present invention relates to the use of tiotropium salts in combination with salts of salmeterol for the manufacture of a medicament for the treatment of dyspnea.Type: ApplicationFiled: August 3, 2006Publication date: February 7, 2008Applicant: Boehringer Ingelheim International GmbHInventor: Piet Cornelissen
-
Publication number: 20080008772Abstract: The present invention relates to compositions that comprise immediate release and extended release guaifenesin, and extended release hydrocodone bitartrate. The present invention also includes methods for using these compositions for treatment of patients suffering from, for example and without limitation, coughing, sneezing, rhinorrhea, and/or nasal obstruction.Type: ApplicationFiled: July 5, 2006Publication date: January 10, 2008Inventors: John A. Giordano, Kevin M. Brown
-
Patent number: 7309755Abstract: A method for making a polycarbonate article is described wherein the article is made by rotation molding a melt polycarbonate having a weight average molecular weight from 25,000 to about 36,000. The melt polycarbonate is produced by transesterifying a diaryl carbonate and a dihydroxy compound in the presence of a catalyst system to form an intermediate aromatic polycarbonate, wherein the catalyst system comprises a first catalyst selected from the group consisting of alkali metal salts and alkaline earth metal salts; and a second catalyst selected from the group consisting of quaternary ammonium compounds and quaternary phosphonium compounds; adding to said intermediate aromatic polycarbonate a catalyst quencher, and rotation molding the aromatic polycarbonate at a temperature from about 305° C. to about 360° C. Also disclosed are polycarbonate light diffusive articles produced by rotation molding.Type: GrantFiled: August 24, 2005Date of Patent: December 18, 2007Assignee: General Electric CompanyInventor: Johannes Martinus Dina Goossens
-
Publication number: 20070286909Abstract: Compositions are described herein that are nutritional supplements that contain free amino acids. These supplements contain a homogenous mixture of free amino acids, wherein the free-form amino acids comprise L-Lysine, L-Valine, L-Tryptophan, L-Phenylalanine, L-methionine, L-Leucine, L-Threonine, L-Isoleucine, L-Arginine, L-Histidine, L-Tyrosine, L-Carnitine, L-Serine, L-Glutamine, Aspartic Acid, L-Proline, L-Glycine, Taurine, L-Cysteine, Gamma-aminobutyric acid (GABA), L-Alanine, L-Glutamic acid, and wherein the composition comprises at least one B vitamin. These compositions are of use to treat disorders associated with a deficiency at least one amino acid, such as soft tissue injury, insomnia, panic attacks, anxiety disorders, eating disorders, anorexia, depression, chronic pain, emotional distress, chemical dependence, alcoholism, and hypoglycemia.Type: ApplicationFiled: June 7, 2007Publication date: December 13, 2007Inventors: Daniel S. Smith, Timothy Kuss, Julia Ross
-
Publication number: 20070280996Abstract: A dietary supplement that includes a container having a first compartment and a second compartment. The first compartment includes an aqueous medium. The second compartment includes an ingredient that is stable when stored within the second compartment. The container is configured such that a user may selectively cause the first and second compartments to be in communication with each other such that the ingredient of the second compartment is mixed with the aqueous medium of the first compartment. The ingredient, which may be creatine or a derivative thereof, is less stable after being mixed with the aqueous medium of the first compartment.Type: ApplicationFiled: May 30, 2006Publication date: December 6, 2007Inventors: Paul T. Gardiner, Marvin A. Heuer, Shan Chaudhuri, James D. Ramsbottom
-
Publication number: 20070265339Abstract: The present invention relates to a storage-stable aqueous or gel-like composition or solution comprising a magnesium compound selected from a magnesium salt or a magnesium complex compound, and L-carnitine, and the use thereof for the preparation of a medicament for supporting metabolism, in particular in muscle tissue, and for supporting muscle structure, and its use as food supplement or in the veterinary sector as animal feed additive, in particular for horses, poultry, pigeons, pigs, cattle, sheep and camels.Type: ApplicationFiled: May 3, 2007Publication date: November 15, 2007Inventor: Gunter Hopf
-
Patent number: 7291347Abstract: A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.Type: GrantFiled: January 18, 2006Date of Patent: November 6, 2007Assignee: WyethInventors: Anthony Francis Hadfield, Syed Muzafar Shah, James Andrew Provost
-
Publication number: 20070202138Abstract: Compositions for antimicrobial, antibacterial, antiviral, fungicidal and sporicidal applications comprise a mixture of alkyl betaine and alkyl amine oxide components together with a protonating agent. The compositions are particularly effective in the treatment and elimination of microorganisms in planktonic cell form as well as in sessile cell form in biofilms. The compositions may be applied in the form of sprays and foams as well as in liquid forms, as a solution or as a balm, as the sole active ingredient or with other active ingredients together with carriers or diluents.Type: ApplicationFiled: February 28, 2007Publication date: August 30, 2007Applicant: BIOFILM INNOVATIONS GROUP, LLCInventor: Lawrence A. Funt
-
Publication number: 20070202177Abstract: Antimicrobial compositions for use in locking catheters and other devices are provided. In some embodiments, the composition includes at least one alcohol, at least one biocidal agent which is not an alcohol, and one or more poloxamers; in other embodiments, the composition comprises at least one poloxamer and at least one alcohol. The composition can provide long-lasting antimicrobial activity. Methods of using the composition are also provided.Type: ApplicationFiled: February 27, 2007Publication date: August 30, 2007Applicant: BECTON, DICKINSON AND COMPANYInventor: Minh Quang Hoang
-
Publication number: 20070196508Abstract: The present invention relates to a dietary supplement that comprises at least Creatine or derivatives thereof, Taurine or derivatives thereof and a source of Phosphate. The dietary supplement may further comprise one or more of the following: Double Fermented Triticum aestivum, Dextrose, Isomalt, Trehalose, D-Mannose, Mulberry extract, Enicostemma littorale Blume, Scoparia dulcis, Tarragon extract, Andrographis paniculata, Chromium or derivatives thereof, Glutamine and Alpha Lipoic Acid. The present invention may also provide a method for increasing Creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and aiding in recovery following exercise as well as supporting the immune system during periods of intense training.Type: ApplicationFiled: September 14, 2006Publication date: August 23, 2007Inventors: Marvin A. Heuer, Kenneth Clement, Shan Chaudhuri, James D. Ramsbottom, Megan K. Thomas
-
Patent number: 7244765Abstract: The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use.Type: GrantFiled: June 24, 2005Date of Patent: July 17, 2007Assignee: Cytokine Pharmasciences, IncInventor: Thais M. Sielecki-Dzurdz
-
Patent number: 7244764Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.Type: GrantFiled: June 18, 2004Date of Patent: July 17, 2007Assignee: Neurochem (International) LimitedInventors: Xianqi Kong, Walter A. Szarek, Francine Gervais
-
Patent number: RE41339Abstract: Compositions comprising N-acetyl-aldosamines, N-acetylamino acids, and related N-acetyl compounds are useful to alleviate or improve various cosmetic conditions and dermatological disorders, including changes or damage to skin, nail and hair associated with intrinsic aging and/or extrinsic aging, as well as changes or damage caused by extrinsic factors. N-acetyl-aldosamines, N-acetylamino acids, and related N-acetyl composition may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects.Type: GrantFiled: November 1, 2006Date of Patent: May 18, 2010Assignee: Tristrata, Inc.Inventors: Ruey J. Yu, Eugene J. Van Scott